Kathleen Moore to Risk Assessment
This is a "connection" page, showing publications Kathleen Moore has written about Risk Assessment.
Connection Strength
0.215
-
Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):591-600.
Score: 0.121
-
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2014 07; 3(4):284-9.
Score: 0.094